Granules India Limited · NSE:GRANULES
Granules India — Q1 FY22 Earnings Presentation
17 slides from Granules India's earnings presentation, Jul 27, 2021
Slide 1: Cover letter to stock exchanges
Gg GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, INDIA. Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471 Dated July 27, 2021 To, National Stock Exchange
Slide 2: Granules India Limited Q1FY22 Earnings Presentation
Granules India Limited Q1FY22 Earnings Presentation 1
Slide 3: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Q1FY22 - Financial Highlights
Q1FY22 - Financial Highlights (In ₹ Mn) Income from Operations Gross margin and margin % EBITDA and EBITDA margins 4,700 2,100 26.0% 4,600 64.0% 15.5% 8,498 4,500 2,000 4,400 62.0% 1,900 4,300 59.5% 1,800 4,200 4,100 60.0% 1,700 25.0% 7,356 4,000 3,900 58.0% 1,600 3,800 24.0% 1,500 3,700 54.2% 56.0%
Slide 5: Q1FY22 - Revenue split by Market, Molecules and Segments
Q1FY22 - Revenue spilt by Market, Molecules and Segments Growth momentum witnessed in North America Finished Dosage and PFI segments grew 25% and 18% (In ₹ Mn) 7,356 8,498 7,356 8,498 Geographical Mix 53.1% Segment Revenue 51.9% 4,545 19.1% 16.8% 3,856 13.8% 11.7% 11.4% 10.9% 5.9% 5.4% 1,379 1,716 2
Slide 6: Q1FY22 - Key Financial and Business Highlights
Q1FY22- Key Financial and Business Highlights • Successfully completed USFDA inspection for its Virginia facility on 20th Jul’21 and EIR received. • Paracetamol KSM supply disruption has continued and affected our Revenue and PAT adversely. The KSM supply situation is likely to improve with an incre
Slide 7: Q1FY22 - Key financial ratios
Q1FY22- Key financial ratios (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Operational Cash Flow Free Cash Flow * 6,500 6,298 0.9 6,400 6,300 6,133 6,121 0.9 0.9 1,453 522 506 6,200 5,998 0.8 0.8 6,100 0.8 0.8 6,000 5,900 5,752 0.8 0.8 1,328 373 5,800 0.7 0.8x 0.8x 5,700 0.7 0.7 5,600 5,500 0.7 0.7 5,
Slide 8: 5 years Revenue – Contribution from Core vs other molecules
5 years Revenue – Contribution from Core vs other molecules 14% 14% 15% 16% 3% 3% 17% 18% 34% 26% 16% 3% 29% 23% 5% 15% 25% 4% 21% 33% 17% 86% 86% 85% 84% 19% 83% 5% 6% 29% 34% 14% 17% 1% 30% 5% 34% 14% 14% 3% FY'17A FY18A FY'19A FY'20A FY'21A Para MF IBU GGF MCB Others Core Others FY'17 FY18 FY'19
Slide 9: ANDA/Dossier filing status as of June'21
ANDA/Dossier filing status as of June’21 GPI IP GIL IP Filing Status USA USA Europe Canada South Africa UK Total Approved 19 24 2 1 46 Tentatively Approved 1 1 2 To be approved 8 4 3 2 2 2 21 Total Products 28 29 5 3 2 2 69 Total GPI products include: CII – 7 PFOS – 4 Liquid Orals - 3 IMS value for
Slide 10: Improving returns; focus on OCF generation for funding capex
Improving returns; focus on OCF generation for funding capex while meeting increased working capital requirement: 5-year trajectory (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 8,704 9,082 135 125 2,919 114 117 1,615 3.1x 109 6,138 6,058 5,752 2.4x 2.1x
Slide 11: 5-year trajectory: Creating value for stakeholders
5-year trajectory: Creating value for stakeholders (In ₹ Mn) 5-year CAGR 19% 5-year CAGR 23% 32,375 50.7% 57.0% Gross Profit Margins Gross Profit and 25,986 44.9% 22,792 Revenue 16,918 52.6% 47.0% 13,177 18,463 14,353 10,236 7,955 7,556 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 5-year CAGR 2
Slide 12: Increasing share from FDs while focussing on backward integration
Increasing share from FDs while focussing on backward integration (In ₹ Mn) Higher revenue contribution coming from regulated market, 72% of total revenues Total Revenue 14,353 16,918 22,792 25,986 32,375 11,113 17,451 13,879 6,612 6,010 5,674 5,055 4,573 4,525 4,083 4,029 3,795 3,550 3,367 2,925 2,
Slide 13: ESG Journey - Granules
ESG Journey - Granules 80 68 69 63 59 57 52 52 53 53 45 44 41 37 36 31 Environmental Social Governance Overall Highest in Pharma Median in Pharma Lowest in Pharma Granules Source: S&P Global CRISIL Ranking Our efforts have been recognized by CRISIL, an S&P Global company, with a healthy score among
Slide 14: CSR Initiatives
CSR Initiatives As a part of CSR initiative, we have donated Paracetamol tablets to the government of Telangana for fighting against COVID 13
Slide 15: In Summary
In Summary 2–3-year Financial Goals: Revenue CAGR ~20%+ PAT CAGR ~20%+ Timely launches of products expected ROCE ~25%+ Focus on Cash conservation and FY22 while increasing the market share liquidity management of existing products by passing on cost Focus on Free cash flow generation and benefits re
Slide 16: Glossary
Glossary API: Active Pharmaceutical Ingredient PFI: Pharmaceuticals Formulation Intermediates FD: Finished Dosage OTC: Over the counter drugs Rx: Prescription drugs IR: Immediate Release ER: Extended Release CII: Control substances PFOS: Powder for oral suspensions and solutions MUPS: Multi-unit pel
Slide 17: Thank you
Thank you Granules India Ltd Granules India IR Gauri Kanikar Floor 2 Block 3 My Home Hub Krishna Raghunathan Consulting Madhapur Hyderabad 500081 Granules India Ltd Ernst & Young Investor Relations Practice CIN: L24110TG1991PLC012471 VP Finance and Investor Relations Voice: +91 40 30660000/30663600